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Historic milestones in the
evolution of the crossmatch
The introduction of the serologic crossmatch—first proposed by 
Hektoen (1907) and first performed by Ottenberg (1908)—made 
it possible to transfuse blood without fear of unpredictable and 
potentially disastrous acute hemolytic reactions, most of which 
were attributable to direct agglutinating (IgM) anti-A, anti-B, or 
anti-A,B. Previously transfused or previously pregnant recipients 
continued to experience sporadic hemolytic transfusion reactions 
as a result of “incomplete” (IgG) blood group antibodies. Coombs’ 
introduction of the antiglobulin test (1945) made it possible to 
detect “incomplete” (IgG) antibodies and to develop laboratory 
methods to identify and transfuse serologically compatible RBCs. 
During the past 50 years, the antibody screen has evolved to be 
more effective than the crossmatch for detecting the presence of 
potential serologic incompatibility and has, in fact, replaced the 
crossmatch as the key step in pretransfusion compatibility testing. 
The antibody screen has become the serologic surrogate for the 
crossmatch and, currently, the computer crossmatch is becoming 
the electronic surrogate for the crossmatch. In historical perspec-
tive, the past 100 years witnessed the rise and fall of the cross-
match. Today, hemolytic transfusion reactions are more likely to 
be the result of misidentifying the intended transfusion recipient 
than of failure of routine compatibility testing to detect serologic 
incompatibility. The introduction of the serologic crossmatch—100 
years ago—had a major positive impact on all aspects of clinical 
medicine. As a result of these advances, we are quickly approach-
ing the limits of improving the safety and efficacy of blood trans-
fusions by conventional serologic methods. Future improvements 
are more likely to be the result of applications of molecular geno-
typing—which could not have become available at a more perfect 
time. When Immunohematology publishes its 50th-anniversary 
issue, the improvements in transfusion science are more likely to 
be based on molecular methods than on conventional blood bank 
serology. Immunohematology 2009;25:147–151. 
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The pretransfusion serologic crossmatch as we know it—direct mixing of a donor’s RBCs and the intended recipient’s serum or plasma—is fading into history. 
The development of increasingly sensitive antibody screen-
ing methods, ready availability of commercially marketed 
reagent RBC screening panels, and acceptance of computer 
crossmatches by accreditation and regulatory authori-
ties have significantly diminished the role of the serologic 
crossmatch in compatibility testing. The following review 
highlights historic milestones that contributed to the devel-
opment of the crossmatch as a key step in routine compat-
ibility testing. More recently, other scientific events have 
contributed to replacing the serologic crossmatch with im-
proved antibody screens as serologic surrogates and com-
puter crossmatches as electronic surrogates. As this review 
encompasses more than a century’s history in only a few 
pages, the authors were obliged to be selective in highlight-
ing important changes. We recognize this limitation and 
direct readers who seek more information to the original 
articles cited in the references.
Historical Origins of the Crossmatch
 In 1907, Ludwig Hektoen, a pathologist at Chicago’s In-
stitute for Infectious Diseases, suggested, for the first time 
on record, that direct matching of donors’ and recipients’ 
blood could prevent the potential adverse effects that had 
been observed after many blood transfusions.1,2 Comment-
ing on Landsteiner’s observation that the serum of some 
persons agglutinated the RBCs of certain others, Hektoen 
speculated that “under special conditions, homologous 
transfusion might prove dangerous by leading to agglutina-
tion within the vessels of the subject transfused.”1 Although 
Hektoen did not perform actual serologic crossmatches, 
historians credit him as being the first physician to propose 
direct pretransfusion donor-recipient crossmatching.3–5 Be-
fore Hektoen’s suggestion, transfusions of animal or human 
blood had been conducted without pretransfusion sero-
logic testing and, as might be anticipated, some transfu-
sions appeared to be beneficial, but others were disastrous.6 
Only a few years before Hektoen’s proposal, Landsteiner 
had succeeded in differentiating human RBCs into three 
serologic groups (A, B, O),7 but neither Landsteiner nor 
other contemporary laboratory investigators linked the 
serologic differences between human RBCs to the cause of 
sporadic hemolytic transfusion reactions. In 1908, Otten-
berg performed the first serologic crossmatch on record, 
mixing the blood of a wife (donor) and her husband (re-
cipient) and observing the absence of hemolysis before an 
uneventful 17-minute direct donor-recipient transfusion.8 
Ottenberg did not provide details of how he performed the 
first pretransfusion donor-patient crossmatch, but he pro-
posed “that a thing much to be desired is, that a convenient 
clinical test for this purpose be devised.”8 Physicians were 
slow to recognize the potential importance of pretransfu-
sion serologic testing for preventing hemolytic transfusion 
reactions. Among the skeptics was George Crile, a surgeon 
in Cleveland, who had pioneered direct patient-to-recipient 
transfusions.9 Crile wrote “contrary to common belief, 
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normal blood of one individual does quite as well as that of 
another. Kinship apparently is of no special advantage.”10 
The Indirect Antiglobulin Test and Its Modifications
 Ottenberg’s approach of pretransfusion serologic 
matching of donor’s RBCs and recipient’s serum was slowly 
accepted by surgeons and obstetricians, who performed 
most transfusions at that time. During the next four 
decades, pretransfusion serologic crossmatching was grad-
ually introduced in hospitals in the United States. By elimi-
nating those donor-recipient incompatibilities that were 
detectable by direct hemagglutination, i.e., ABO incompat-
ibilities, the room-temperature direct crossmatch eliminated 
most acute and disastrous hemolytic reactions. Neverthe-
less, sporadically, a previously transfused or previously 
pregnant transfusion recipient experienced an acute or 
delayed hemolytic transfusion reaction. In 1945, Coombs 
et, al. published their observation that rabbit anti-human 
serum could identify “incomplete” antibodies, and the anti-
human globulin (AHG) phase of donor RBC–recipient serum 
matching was added to procedures for antibody screen-
ing and crossmatching.11 The addition of an AHG phase to 
compatibility testing was a major advance; and the AHG 
phase remains the most effective of all laboratory methods 
for ensuring serologic compatibility of ABO-matched RBC 
transfusions. Soon, other investigators proposed modifica-
tions of the antibody screen to increase its sensitivity for 
detecting blood group antibodies. Among the more notable 
modifications were the addition of albumin,12,13 trypsin,14,15 
papain,16 dextran,17 ficin,18 bromelin,19 low-ionic-strength 
solution (LISS),20 polyethylene glycol (PEG),21 and hexadi-
methrine bromide.22 Editors of the first edition of the Amer-
ican Association of Blood Banks’ (AABB) Standards for a 
Blood Transfusion Service (1958) required a major cross-
match, but the minor crossmatch was optional.23 For the 
major crossmatch, “at least two methods shall be used, one 
to demonstrate optimally the presence of serum or saline 
active antibodies, and another to detect the presence of in-
complete (blocking) antibodies.”23 The acceptable methods 
were as follows:23
A saline or serum crossmatch with 2% donor RBCs, 1. 
read at room temperature and after an indirect anti-
globulin test.
A saline or serum crossmatch in addition to a high pro-2. 
tein (bovine albumin) slide test, read on a heated slide 
resting on a view box.
Both a saline or serum crossmatch and a tube technic 3. 
(recipient’s serum, albumin, and donor’s RBCs incu-
bated for 10 to 20 minutes, centrifuged, and read).
The third edition of Standards (1962) recognized “enzyme 
systems” as an option for antibody screening for the first 
time and introduced the requirement that the “antiglobulin 
system [for crossmatching] shall utilize antihuman serum 
meeting N.I.H. standards….”24
The Antibody Screen as a Surrogate for the Serologic Cross-
match
 Commercially marketed panels of reagent RBCs for 
screening for blood group antibodies began to appear in the 
United States in the late 1950s and early 1960s. In 1962, for 
the first time, Standards (3rd edition) recognized a limited 
role for reagent RBCs for the detection of antibodies in pa-
tients’ sera.24 The Standards’ acceptance of reagent RBCs as 
a surrogate for the direct crossmatching of donor RBCs and 
patients’ sera was not without controversy. Grove-Rasmussen 
communicated his concern in Transfusion, commenting 
that stored reagent RBCs may not be “in as good condition” 
as freshly donated RBCs and may not express all pertinent 
antigens.25
Alternatives to Testing for Hemagglutination in Test Tubes  
 From the outset, antibody screens and crossmatches in 
US hospitals were performed mostly in test tubes and, less 
frequently, by rapid slide method. Alternative formats have 
been introduced, primarily to decrease the volume of re-
agents. These methods include capillary tubes,26 microtiter 
plates,27 solid-phase plates,28 and gel agglutination.29 How-
ever, only the microplate method has been used extensively 
as an alternative for crossmatching.30, 31
The Rise of the Antibody Screen and the Fall of the Serologic 
Crossmatch
 As methods to improve the sensitivity of the antibody 
screen improved, the importance of a direct serologic cross-
match of donor’s RBCs and recipient’s plasma became less 
critical. In fact, from the first proposal of the pretransfu-
sion crossmatch until the present, direct serologic match-
ing of donor’s RBCs and patient’s serum or plasma has 
been recognized as a highly desirable, but not absolutely 
required, step in issuing RBCs for transfusion. Among the 
clinical situations in which the crossmatch is often omitted 
are life-threatening hemorrhages,32 after massive transfu-
sions when most of the recipient’s blood has been replaced 
by donor’s blood,32 and for infants younger than 4 months 
of age.33 In 1980, Winn and colleagues proposed that an ex-
tended antibody screen could replace the crossmatch if the 
results of ABO typing and antibody screen were verified and 
documented.34 In 2000, Kuriyan and Fox reported their ex-
perience transfusing RBCs without a serologic crossmatch 
if the antibody screen was negative and if the ABO was 
confirmed by two technologists.35 In their hospital, elimi-
nating the crossmatch decreased the cost of compatibility 
testing 40 percent ($32,968); retaining the immediate-
spin crossmatch saved 30 percent ($24,748). In a larger 
hospital, eliminating the AHG crossmatch after a negative 
antibody screen saved $70,000 per year.36 In 1985, Shul-
man and colleagues reported the effect of switching from 
a conventional crossmatch (readings after immediate spin, 
37°C incubation, and AHG phase) to an abbreviated crossmatch 
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(immediate spin only) for patients without blood group al-
loantibodies.36 During an 8.5-month experience, they per-
formed 27,742 crossmatches and avoided 46,959 unnec-
essary crossmatches, decreasing costs by at least $49,300 
annually. In 1992, Judd and colleagues published a study 
entitled “Can the reading for serological reactivity follow-
ing 37°C incubation be eliminated?”37 Before conducting 
the study, they had the impression that the 37°C reading 
contributed minimally to transfusion safety. However, af-
ter their review identified approximately 25 patients with 
37°C-only antibodies with Rh, Kell, or Kidd specificity an-
nually, they decided to retain the 37°C reading. Seven years 
later, Judd and colleagues revisited the issue.38 Using data 
from prior publications, they estimated the risk that elimi-
nating different components of the compatibility test would 
introduce in their hospital. The result was that the risk for 
transfusing incompatible blood by eliminating the direct 
AHG test, the indirect AHG crossmatch, and 37°C read-
ing would be approximately 1:13,000, 1:2,000, and 1:2,400 
units transfused.38 Given this history of scientific and tech-
nical events, what is the current state of the art? Not all pro-
posed variations of the serologic crossmatch have survived 
the test of time. In 2008, the College of American Patholo-
gists distributed a proficiency survey that consisted of a 
donor RBC sample (J-13R) to be crossmatched with a pa-
tient’s serum sample (J-10S) containing an unknown anti-
body (anti-Jka).39 Of 2,572 laboratories reporting results for 
antibody screening, 874 (34.0%) used a tube method; 94 
(3.7%), solid-phase red cell adherence (SPRCA); and 1604 
(62.3%), gel agglutination. For those using a tube method, 
27 (3.0%) used saline AHG; 54 (6.2%), albumin AHG; 561 
(64.1%) used LISS AHG; and 234 (26.7%) used PEG AHG. 
Having identified (or misidentified) the anti-Jka, 1821 labo-
ratories reported performing an AHG crossmatch. Of these, 
107 (5.9%) used saline AHG; 137 (7.6 %), albumin AHG; 
1201(65.9%), LISS AHG; and 376 (20.6%) PEG AHG).39 
Notably, the number of hospitals using enzyme-treated re-
agent RBCs for routine antibody screening was too few to 
be listed as a separate category.
 
Automated Crossmatching
 The first widely used automated serologic analyzer 
performed ABO grouping and Rh(D) typing, but not cross-
matching.40 The first automated analyzer that did incorpo-
rate the option for a serologic donor RBC–recipient plasma 
crossmatch was the ABS2000 (Immucor, Norcross, GA).30, 31 
Most hospitals that acquired an ABS2000, including our 
hospital, did not take advantage of the crossmatch option, 
preferring a manual immediate-spin crossmatch for pa-
tients with negative AHG antibody screens as a more prac-
tical alternative.
Eliminating the Crossmatch: the Computer Crossmatch
 In 1991, Judd published an editorial asking the ques-
tion, “Are there better ways than the crossmatch to dem-
onstrate ABO incompatibility?”41 Shortly thereafter, Butch, 
Judd, and colleagues at Blood Bank at the University of 
Michigan Hospital initiated a procedure to confirm donor-
recipient compatibility by electronic verification, i.e., by a 
computer crossmatch.42 In 1994, these investigators report-
ed their experience using a computer crossmatch for pre-
transfusion tests for 14,021 patients between February 1992 
and March 1993. Their report included a detailed standard 
operating procedure, consisting of specific requirements for 
(1) RBC unit processing, (2) patient sample processing, (3) 
crossmatch for ABO compatibility, and (4) release of RBC 
units for transfusion. As suggested by Judd’s 1991 editorial, 
the key remaining function of the serologic crossmatch was 
ensuring ABO compatibility for RBC transfusions. The func-
tion of detecting antibodies in the recipient’s serum against 
antigens on donors’ RBCs had been co-opted by the anti-
body screen. Although AABB Standards allowed computer 
crossmatching to replace the immediate-spin crossmatch by 
the 15th edition (1993),43 the logistics of writing software for 
individual hospital information systems limited widespread 
implementation.42 In 1998, Judd reported to attendees of 
the International Society of Blood Transfusion’s congress in 
Hong Kong that there were electronic crossmatching proce-
dures in use in at least 10 North American facilities, Scandi-
navia, Hong Kong, and Australia.44 Progress in widespread 
implementation of the computer crossmatch has been slow, 
but the historic milestone has been established as many 
blood banks have moved forward.
Impact of Serologic Methods on Clinical Practice 
 We now change gears, moving from an objective his-
tory of the serologic crossmatch to more subjective opin-
ions about how these historic milestones have impacted the 
practice of medicine. Surely, the starting point is Hektoen’s 
suggestion that Landsteiner’s newly described serologic 
blood groups may be related etiologically to observations of 
unpredictable acute hemolytic reactions after certain blood 
transfusions. When Ottenberg moved Hektoen’s sugges-
tion forward and performed the first serologic crossmatch, 
he initiated the era of safe blood transfusion. It was now 
possible to perform surgery and treat hemorrhage with-
out the fear of an unpredicted, acute, and potentially fatal 
hemolytic reaction. Coombs’ development of antihuman 
globulin provided the next major impact, significantly de-
creasing the risk of hemolytic reactions attributable to non-
ABO IgG blood group antibodies. By 1945, transfusions of 
RBCs could be administered without fear of an ABO-
related acute hemolytic reaction, and severe reactions from 
non-ABO antibodies were relatively uncommon. With the 
risk of acute and delayed hemolytic reactions greatly de-
creased, surgeons were not only able to manage trauma, 
obstetrical hemorrhage, and gastrointestinal bleeding, but 
also to develop procedures for previously impossible car-
diovascular and cancer surgeries requiring large numbers 
of blood transfusions. Subsequent refinements in methods 
for antibody screening and identification, although a major 
focus in the blood banking community, have had only an 
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incremental impact on the practice of medicine. Even the 
introduction of the computer crossmatch—clearly a major 
advance for efficient management of pretransfusion labo-
ratory testing—has only a minor impact, if any, on clinical 
practice.
 After 100 years of some broad strides and many in-
cremental improvements, the serologic crossmatch has 
evolved to a standardized, highly sensitive, and safe labora-
tory practice. The heyday of discovering new blood group 
antigens and developing incrementally more sensitive se-
rologic methods may be passing, but there are new and 
challenging opportunities for transfusion science and blood 
banking. The availability of molecular genotyping to fur-
ther define blood group antigens has opened new vistas for 
blood group science.45 Molecular science offers the promise 
of improved efficacy of transfusions of RBCs, particularly 
for those chronically transfused patients for whom con-
ventional compatibility testing does not ensure satisfactory 
outcomes. As we look back and honor the contributions of 
our colleagues in this 25th anniversary issue of Immunohe-
matology, we can only speculate on what further advances 
will be published in future issues of Immunohematology 
and featured in the next historical review.
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